In this study, we investigated the oncolytic activity of six FAKi currently being evaluated in clinical trials, using various pancreatic tumor cell lines and examined whether tumor cell killing can be enhanced through combination with PD-H. This evidence concerns the gene PDP1 and pancreatic neoplasm.